头孢替吡咯在加拿大的使用情况:CLEAR 研究的最终结果。

IF 4.2 2区 医学 Q1 INFECTIOUS DISEASES
George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky
{"title":"头孢替吡咯在加拿大的使用情况:CLEAR 研究的最终结果。","authors":"George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2024.2374280","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.</p><p><strong>Research design and methods: </strong>The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).</p><p><strong>Results: </strong>In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).</p><p><strong>Conclusions: </strong>In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How is ceftobiprole used in Canada: the CLEAR study final results.\",\"authors\":\"George G Zhanel, Justin Kosar, Melanie Baxter, Rita Dhami, Sergio Borgia, Neal Irfan, Gordon Dow, Maxime Dube, Teagen Rolf von den Baumen, Carlo Tascini, Anna Lee, Zain Chagla, Gabriel Girouard, Samuel Bourassa-Blanchette, May Wu, Yoav Keynan, Andrew Walkty, James A Karlowsky\",\"doi\":\"10.1080/14787210.2024.2374280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.</p><p><strong>Research design and methods: </strong>The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).</p><p><strong>Results: </strong>In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).</p><p><strong>Conclusions: </strong>In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.</p>\",\"PeriodicalId\":12213,\"journal\":{\"name\":\"Expert Review of Anti-infective Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anti-infective Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14787210.2024.2374280\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2374280","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:我们报告了加拿大国家 CLEAR(加拿大抗菌药物实际使用领导力)登记数据中头孢比普洛在加拿大患者中临床使用的最终结果:研究设计与方法:作者通过国家伦理批准的 CLEAR 研究审查了最终数据。此后,作者通过 PubMed 调查了有关使用头孢比普洛治疗传染病患者的文献(截至 2024 年 3 月):在加拿大,头孢替比普乐主要用于治疗由 MRSA 引起的各种严重感染。它主要用于既往未使用过抗菌药物的患者,经常与达托霉素和/或万古霉素合用,具有很高的微生物学和临床治愈率以及极佳的安全性。多份报告证实了头孢比普乐的微生物学/临床疗效和安全性。据报道,头孢比普洛还可用于社区获得性细菌性肺炎(CABP)和医院获得性细菌性肺炎(HABP)患者的经验治疗:结论:在加拿大,头孢比普洛主要用于治疗由 MRSA 引起的各种严重感染,适用于既往未使用过抗菌药物的患者。它经常与达托霉素和/或万古霉素联合使用,微生物/临床治愈率高,安全性极佳。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How is ceftobiprole used in Canada: the CLEAR study final results.

Background: We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.

Research design and methods: The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).

Results: In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).

Conclusions: In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信